Latest news with #Kalorama
Yahoo
23-06-2025
- Business
- Yahoo
New Data Signals IVD Growth in a Shifting Market Amid Tariff Uncertainty
Kalorama Identifies Point-of-Care Testing Momentum and Strategic Blind Spots in Latest Diagnostic Trends Analysis ARLINGTON, Va., June 23, 2025 /PRNewswire/ -- With healthcare markets under pressure from newly implemented tariff policies, ongoing regulatory changes, and broader economic uncertainty, recent data from Kalorama Information reveals early indicators of where diagnostic demand may be headed next—and why industry leaders must closely monitor these shifts to adapt effectively. Kalorama's latest analysis, featured in the 2025 IVD Trends and Market Update, shows sustained growth in point-of-care (POC) testing, signaling more than just segment-level performance—it reflects deeper structural changes in how and where care is being delivered. The growing demand for decentralized testing suggests that providers are prioritizing faster, near-patient diagnostics in response to system-wide efficiency pressures, shifting care models, and increasing patient expectations. These changes—compounded by newly enacted trade policies and regulatory fluctuations—are prompting diagnostic companies to reevaluate not just product development pipelines, but also commercial strategy, customer alignment, and market positioning. The insights are featured in a free data highlight from the 2025 IVD Trends and Market Update, available now: Download the data highlight or explore the full report here: IVD Market Update 2025. With tariffs in effect and regulatory frameworks still in flux, the clinical diagnostics market is in a period of continuous adjustment. As customer decision-making evolves alongside market conditions, it has become critical for manufacturers to not only interpret where the market is heading—but to reassess how these forces are influencing their customers' needs and expectations. Kalorama's data illustrates that while trendlines can identify areas of growth—such as the momentum in POC testing—they do not on their own provide the full context needed to make targeted strategic decisions. These signals serve as a foundation but must be tracked and evaluated over time to inform business decisions about product direction, customer engagement, and market expansion. Kalorama has observed that companies successfully navigating tariff-related disruption and broader economic shifts are those actively: Realigning their commercial and product strategies with newly emerging or shifting provider priorities Adjusting to changes in purchasing behavior driven by tariff implementation and regulatory change Reevaluating product development focus and positioning based on up-to-date insight into segment viability and growth trajectories "This is a time for proactive reassessment," said Alisa Alvich, Marketing Director at Kalorama, part of Science and Medicine Group. "The diagnostic companies that are outperforming right now are the ones continuously tracking how market signals evolve—and using that intelligence to stay aligned with what their customers are actually experiencing and prioritizing." While the data highlight reflects current trends in diagnostic testing, Kalorama emphasizes that real strategic clarity comes from pairing syndicated market insights with tailored, business-specific intelligence that can guide decisions about pricing, product roadmaps, and market entry. About Kalorama Information Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers. View original content to download multimedia: SOURCE Kalorama Information
Yahoo
23-06-2025
- Business
- Yahoo
New Data Signals IVD Growth in a Shifting Market Amid Tariff Uncertainty
Kalorama Identifies Point-of-Care Testing Momentum and Strategic Blind Spots in Latest Diagnostic Trends Analysis ARLINGTON, Va., June 23, 2025 /PRNewswire/ -- With healthcare markets under pressure from newly implemented tariff policies, ongoing regulatory changes, and broader economic uncertainty, recent data from Kalorama Information reveals early indicators of where diagnostic demand may be headed next—and why industry leaders must closely monitor these shifts to adapt effectively. Kalorama's latest analysis, featured in the 2025 IVD Trends and Market Update, shows sustained growth in point-of-care (POC) testing, signaling more than just segment-level performance—it reflects deeper structural changes in how and where care is being delivered. The growing demand for decentralized testing suggests that providers are prioritizing faster, near-patient diagnostics in response to system-wide efficiency pressures, shifting care models, and increasing patient expectations. These changes—compounded by newly enacted trade policies and regulatory fluctuations—are prompting diagnostic companies to reevaluate not just product development pipelines, but also commercial strategy, customer alignment, and market positioning. The insights are featured in a free data highlight from the 2025 IVD Trends and Market Update, available now: Download the data highlight or explore the full report here: IVD Market Update 2025. With tariffs in effect and regulatory frameworks still in flux, the clinical diagnostics market is in a period of continuous adjustment. As customer decision-making evolves alongside market conditions, it has become critical for manufacturers to not only interpret where the market is heading—but to reassess how these forces are influencing their customers' needs and expectations. Kalorama's data illustrates that while trendlines can identify areas of growth—such as the momentum in POC testing—they do not on their own provide the full context needed to make targeted strategic decisions. These signals serve as a foundation but must be tracked and evaluated over time to inform business decisions about product direction, customer engagement, and market expansion. Kalorama has observed that companies successfully navigating tariff-related disruption and broader economic shifts are those actively: Realigning their commercial and product strategies with newly emerging or shifting provider priorities Adjusting to changes in purchasing behavior driven by tariff implementation and regulatory change Reevaluating product development focus and positioning based on up-to-date insight into segment viability and growth trajectories "This is a time for proactive reassessment," said Alisa Alvich, Marketing Director at Kalorama, part of Science and Medicine Group. "The diagnostic companies that are outperforming right now are the ones continuously tracking how market signals evolve—and using that intelligence to stay aligned with what their customers are actually experiencing and prioritizing." While the data highlight reflects current trends in diagnostic testing, Kalorama emphasizes that real strategic clarity comes from pairing syndicated market insights with tailored, business-specific intelligence that can guide decisions about pricing, product roadmaps, and market entry. About Kalorama Information Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers. View original content to download multimedia: SOURCE Kalorama Information Sign in to access your portfolio
Malaysian Reserve
20-06-2025
- Health
- Malaysian Reserve
Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care. 'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.' Key Findings from the Report: Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029. Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments. True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment. Why It Matters Now The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes. 'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.' Audience Impact This research is essential for: Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery. With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier. Get the Report Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
Malaysian Reserve
20-06-2025
- Business
- Malaysian Reserve
Infectious Disease Testing Market Remains Dynamic Amid Post-Pandemic Shifts and New Innovations
ARLINGTON, Va., June 19, 2025 /PRNewswire/ — Kalorama Information, a trusted source for healthcare market intelligence, released insights into the evolving global market for infectious disease testing through the In Vitro Diagnostics Business Outlook newsletter. Despite the decline in COVID-19 testing, the overall infectious disease diagnostics market remains robust, supported by sustained demand for non-COVID tests and the adoption of next-generation technologies across both laboratory and point-of-care (POC) settings. With testing essential for diagnosing, monitoring, and containing a wide range of infections—from respiratory illnesses and bloodborne viruses to sepsis and gastrointestinal pathogens—the market continues to attract significant attention and investment. Kalorama's latest report highlights a steady shift in growth drivers, with POC solutions, molecular platforms, and advanced immunoassays gaining ground. 'Infectious disease diagnostics continues to be one of the most innovative segments of the IVD industry,' said Daniel Granderson, Senior Editor of Kalorama Information. 'New technologies are not only enhancing diagnostic speed and accuracy but are also reshaping where and how testing is performed—bringing more solutions to decentralized and resource-limited settings.' Highlights from the article include: Strong global demand for lab-based immunoassays and molecular tests Continued innovation in syndromic panels, microfluidics, and cartridge-based POC platforms A growing share of the market shifting toward emerging regions, with Asia Pacific and other developing areas seeing increased diagnostic infrastructure and demand Major industry players—including Roche, Abbott, Danaher, and QIAGEN—introducing new products to address unmet needs in STIs, sepsis, and respiratory diseases The report also profiles emerging innovators bringing AI-powered diagnostics, rapid sepsis panels, and cost-effective molecular tools to market, emphasizing the industry's ongoing focus on speed, accuracy, and accessibility. For more insights on market forecasts, regional dynamics, and comprehensive market views, visit Kalorama Information's IVD Business Outlook. About IVD Business Outlook In Vitro Diagnostics Business Outlook is a bimonthly publication from Kalorama Information, offering six issues annually—each dedicated to a distinct segment of the IVD industry. Designed for decision-makers across diagnostics and life sciences, the publication delivers exclusive market intelligence, including growth forecasts, market sizing, and share analysis. Each issue features in-depth coverage of diagnostic test categories, company profiles, mergers and acquisitions, regional trends, and expert analysis of key industry developments. With curated insights not found in mainstream sources, In Vitro Diagnostics Business Outlook is an essential resource for staying ahead in the global diagnostics market. About Kalorama InformationKalorama Information, a division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide. Website:
Yahoo
18-06-2025
- Business
- Yahoo
Cardiac Marker Testing Market Poised for Steady Growth, Driven by Point-of-Care Expansion
ARLINGTON, Va., June 18, 2025 /PRNewswire/ -- The global cardiac marker testing market is on track for sustained growth, according to research from Kalorama Information's IVD Business Outlook. As cardiovascular disease remains a leading cause of mortality worldwide, demand for rapid and accurate diagnostic testing continues to rise. Kalorama's latest analysis highlights that while traditional lab-based cardiac marker testing remains the dominant segment, the point-of-care (POC) segment is gaining ground at a faster pace—reflecting growing interest in decentralized and near-patient diagnostics. The article projects continued market expansion through 2029, supported by adoption of high-sensitivity assays and increasing procedure volumes globally. "The shift toward point-of-care cardiac testing reflects a broader transformation in healthcare delivery," said Daniel Granderson, Senior Editor of Kalorama Information. "Providers are seeking faster diagnostic tools that enable quicker clinical decisions, especially in emergency and acute care settings." Cardiac biomarkers such as troponin, BNP, CK-MB, and myoglobin remain central to acute care diagnostics, accounting for the vast majority of test volumes. North America and Europe collectively account for more than three-quarters of global market share, while the Asia Pacific region continues to emerge as a high-potential growth area. The article also profiles major players shaping the market landscape, including Danaher (via Beckman Coulter and Radiometer), Siemens Healthineers, QuidelOrtho, Roche, and Abbott. Recent product launches, regulatory approvals, and shifts in diagnostic testing demand—particularly post-pandemic—are helping to reshape vendor dynamics and innovation priorities. For more insights on market forecasts, regional dynamics, and comprehensive market views, visit Kalorama Information's IVD Business Outlook. About IVD Business OutlookIn Vitro Diagnostics Business Outlook is a bimonthly publication from Kalorama Information, offering six issues annually—each dedicated to a distinct segment of the IVD industry. Designed for decision-makers across diagnostics and life sciences, the publication delivers exclusive market intelligence, including growth forecasts, market sizing, and share analysis. Each issue features in-depth coverage of diagnostic test categories, company profiles, mergers and acquisitions, regional trends, and expert analysis of key industry developments. With curated insights not found in mainstream sources, In Vitro Diagnostics Business Outlook is an essential resource for staying ahead in the global diagnostics market. About Kalorama InformationKalorama Information, a division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide. View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
